Remix Therapeutics

Acquisition, funding and merger involving Remix Therapeutics.

• Remix Therapeutics has just announced a $60 Million fundraising (posted on January 8 2024).
• Remix Therapeutics has just announced a $70 Million fundraising (posted on May 19 2022).

View the org chart displaying its 17 main executives

Most searched biographies at Remix Therapeutics

• Peter Smith, President and Chief Executive Officer
• Michael Rome, Director
• Jeff Goater, Director

Popular executive movements at Remix Therapeutics

• Dominic Reynolds, who was Senior Vice President and Head of Drug Discovery, is promoted to Chief Scientific Officer  (posted on February 2 2024).

Create your alert
to follow the executive moves at Remix Therapeutics.

Remix Therapeutics has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Remix Therapeutics

Social media about Remix Therapeutics

• Remix Therapeutics on Wikipedia, Google News & Yahoo Finance
• Remix Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Peter Smith

Call Remix Therapeutics at +1 617...

View the org chart

Register to receive your alert

Report an error